1,2-Dihydro-2-oxoquinoline derivatives
    1.
    发明授权
    1,2-Dihydro-2-oxoquinoline derivatives 失效
    1,2-二氢-2-氧代喹啉衍生物

    公开(公告)号:US06329525B1

    公开(公告)日:2001-12-11

    申请号:US09555568

    申请日:2000-06-01

    IPC分类号: C07D215227

    摘要: A 1,2-dihydro-2-oxoquinoline derivative represented by the formula: wherein Ar is a pyridyl group or a group represented by the formula: (wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.

    摘要翻译: 由下式表示的1,2-二氢-2-氧代喹啉衍生物:其中Ar是吡啶基或由下式表示的基团:(其中X 3和X 4相同或不同,并且各自为氢原子,卤素 原子,C 1-5烷基,C 1-5烷氧基,羟基或三氟甲基),Y是氮原子,CH或C(OH),R 1和R 2相同或不同,各自相同或不同 氢原子,C 1-10烷基,C 3-15烷氧基烷基或C 3-15烷基氨基烷基,或者R 1和R 2与它们所连接的氮原子一起形成环状氨基,X 1和X 2是 相同或不同,各自为氢原子,C1-5烷基,C1-5烷氧基或卤素原子,或X1和X2一起形成亚烷基二氧基,n为1〜3的整数 ; 或其药学上可接受的盐。

    Nitrogen-containing tetracyclic compounds
    2.
    发明授权
    Nitrogen-containing tetracyclic compounds 失效
    含氮四环化合物

    公开(公告)号:US06281355B1

    公开(公告)日:2001-08-28

    申请号:US09555570

    申请日:2000-06-01

    IPC分类号: A61K31403

    CPC分类号: C07D471/04 C07D495/04

    摘要: A nitrogen-containing tetracyclic compound represented by the formula: wherein Y1—Y2—Y3 is N—C═N or a group represented by the formula: C═C—NR3 (wherein R3 is a hydrogen atom, a C1-5 alkyl group or a nitrogen-containing C2-10 alkyl group), Y4 is S, SO, SO2, CH2 or a group represented by the formula: NR4 (wherein R4 is a C1-5 alkanoyl group or a C1-5 alkyl group), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, and n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

    摘要翻译: 一种由下式表示的含氮四环化合物:其中Y1-Y2-Y3为NC = N或由下式表示的基团:C = C-NR3(其中R3为氢原子,C1-5烷基或 含氮的C2-10烷基),Y4是S,SO,SO2,CH2或由下式表示的基团:NR4(其中R4是C1-5烷酰基或C1-5烷基),R1和R2 各自为氢原子,C 1-10烷基,C 3-15烷氧基烷基或C 3-15烷基氨基烷基,或者R 1和R 2与它们所连接的氮原子一起形成 环状氨基,X1和X2相同或不同,分别为氢原子,C1-5烷基,C1-5烷氧基或卤素原子,n为0,1或2; 或其药学上可接受的盐。

    1,2-dihydro-2-oxoquinoline derivatives
    3.
    发明授权
    1,2-dihydro-2-oxoquinoline derivatives 失效
    1,2-二氢-2-氧代喹啉衍生物

    公开(公告)号:US06380384B1

    公开(公告)日:2002-04-30

    申请号:US09829203

    申请日:2001-04-10

    IPC分类号: C07D40106

    摘要: A 1,2-dihydro-2-oxoquinoline derivative represented by the formula: wherein Ar is a pyridyl group or a group represented by the formula: (wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom; or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.

    摘要翻译: 由下式表示的1,2-二氢-2-氧代喹啉衍生物:其中Ar是吡啶基或由下式表示的基团:(其中X 3和X 4相同或不同,并且各自为氢原子,卤素 原子,C 1-5烷基,C 1-5烷氧基,羟基或三氟甲基),Y是氮原子,CH或C(OH),R 1和R 2相同或不同,各自相同或不同 氢原子,C 1-10烷基,C 3-15烷氧基烷基或C 3-15烷基氨基烷基,或者R 1和R 2与它们所连接的氮原子一起形成环状氨基,X 1和X 2是 相同或不同,并且各自为氢原子,C1-5烷基,C1-5烷氧基或卤素原子; 或者X1和X2一起形成亚烷基二氧基,n为1〜3的整数。 或其药学上可接受的盐。

    4-Tetrahydropyridylpyrimidine derivatives
    6.
    发明授权
    4-Tetrahydropyridylpyrimidine derivatives 失效
    4-四氢吡啶基嘧啶衍生物

    公开(公告)号:US06187781B1

    公开(公告)日:2001-02-13

    申请号:US09381462

    申请日:1999-09-21

    IPC分类号: C07D40144

    摘要: A 4-tetrahydropyridylpyrimidine compound represented by formula (I): wherein Ar represents a phenyl group substituted with 1 to 3 substituents selected from a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, and a trifluoromethyl group, a phenyl group, a thienyl group or a furanyl group; R1 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms; R2 represents an alkyl group having 1 to 5 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms, an alkenyl group having 2 to 5 carbon atoms or an alkynyl group having 2 to 5 carbon atoms; and X1, X2, and X3, which may be the same or different, each represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms, or a pharmaceutically acceptable salt thereof. The 4-Tetrahydropyridylpyrimidine compound finds utility in the treatment of diseases in which CRF is implicated.

    摘要翻译: 由式(I)表示的4-四氢吡啶基嘧啶化合物:其中Ar表示被1至3个选自卤素原子,具有1至5个碳原子的烷基,具有1至5个碳原子的烷氧基的取代基取代的苯基, 和三氟甲基,苯基,噻吩基或呋喃基; R1表示氢原子,碳原子数1〜5的烷基,氨基或被1〜2个碳原子数1〜2的烷基取代的氨基。 R2表示碳原子数1〜5的烷基,碳原子数4〜7的环烷基烷基,碳原子数2〜5的烯基或碳原子数2〜5的炔基。 X 1,X 2和X 3可以相同或不同,分别表示氢原子,卤素原子,碳原子数1〜5的烷基,碳原子数1〜5的烷氧基,烷硫基, 1至5个碳原子的氨基或被1或2个具有1至5个碳原子的烷基取代的氨基,或其药学上可接受的盐。 4-四氢吡啶基嘧啶化合物可用于治疗涉及CRF的疾病。

    Carbamoyl tetrahydropyridine derivatives
    7.
    发明授权
    Carbamoyl tetrahydropyridine derivatives 失效
    氨基甲酰四氢吡啶衍生物

    公开(公告)号:US06894168B2

    公开(公告)日:2005-05-17

    申请号:US10347288

    申请日:2003-01-21

    摘要: Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C5 alkyl group, or the like; Y1—Y2 represents (R4)C═C(R5), (R6)C═N, N═N, (R7) N—CO, or N═C(R8); X1, X2, and X3 are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R3, R4, R5, and R6 are identical or different, and each represents a hydrogen atom or an alkyl group; R7 represents a hydrogen atom, a C1-C5 alkyl group, or the like; and R8 represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.

    摘要翻译: 由下式表示的氨基甲酰基四氢吡啶衍生物:[式中,R 1,R 2和R 2'相同或不同,各自表示氢原子,C 1 C 5 -C 15烷基等; Y 1 - (CH 2)2(R 4 S)(R 5),(R 6) CN,NN,(R 7)N-CO或NC(R 8); X 1,X 2和X 3相同或不同,各自表示氢原子,卤素原子等; R 3,R 4,R 5和R 6相同或不同,并且各自表示氢 原子或烷基; R 7表示氢原子,C 1 -C 5烷基等; 和R 8表示氢原子或氨基甲酰基]或其药学上可接受的盐,以及其制备中间体。 上述衍生物对于被认为涉及CRF的疾病是有效的。

    Carbamoyl tetrahydropyridine derivatives
    8.
    发明授权
    Carbamoyl tetrahydropyridine derivatives 失效
    氨基甲酰四氢吡啶衍生物

    公开(公告)号:US06600038B1

    公开(公告)日:2003-07-29

    申请号:US09914534

    申请日:2001-08-30

    IPC分类号: C07D47334

    摘要: Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C5 alkyl group, or the like; Y1-Y2 represents (R4)C═C(R5), (R6)C═N, N═N, (R7)N—CO, or N═C(R8); X1, X2, and X3 are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R3, R4, R5, and R6 are identical or different, and each represents a hydrogen atom or an alkyl group; R7 represents a hydrogen atom, a C1-C5 alkyl group, or the like; and R8 represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.

    摘要翻译: 由下式表示的氨基甲酰基四氢吡啶衍生物:[式中,R 1和R 2相同或不同,各自表示氢原子,C 1 -C 5烷基等; Y1-Y2表示(R4)C = C(R5),(R6)C = N,N = N,(R7)N-CO或N = C(R8) X1,X2和X3相同或不同,各自表示氢原子,卤素原子等; R3,R4,R5和R6相同或不同,各自表示氢原子或烷基; R7表示氢原子,C1-C5烷基等; 并且R8表示氢原子或氨基甲酰基]或其药学上可接受的盐,并且提供其制备的中间体。上述衍生物对于被认为涉及CRF的疾病是有效的。

    Remedial agent for anxiety neurosis or depression and piperazine derivative
    9.
    发明授权
    Remedial agent for anxiety neurosis or depression and piperazine derivative 失效
    焦虑神经症或抑郁症和哌嗪衍生物的补救剂

    公开(公告)号:US06949552B2

    公开(公告)日:2005-09-27

    申请号:US10311429

    申请日:2001-06-27

    摘要: There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: [wherein Ar1 is a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Ar2 is a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula: (wherein R4 is a hydrogen atom or a halogen atom; and X—Y is CH—NH, CH—O, CH—S or N—O) or a group represented by the formula: (wherein R5 is a hydrogen atom, a hydroxyl group or a C1-10 alkoxy group); R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group, a C3-10 alkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R2 and R3 are the same or different, and are each a hydrogen atom or a C1-10 alkyl group; A-B is N—CH2, CH—CH2, C(OH)—CH2 or C═CH; T1 is a single bond, —N(R6)— (wherein R6 is a hydrogen atom or a C1-10 alkyl group), —O—, —CH═CH— or —C(═O)—; n is an integer of from 1 to 10 and when T1 is a single bond, —CH═CH— or —C(═O)—, n is an integer of from 2 to 10 when T1 is —N(R6)— or —O—], or a pharmaceutically acceptable salt thereof.

    摘要翻译: 提供焦虑性神经症或抑郁症的治疗剂,其包含作为有效成分的MC 4受体拮抗剂; 和由式[1]表示的哌嗪衍生物:其中Ar 1是苯基,取代的苯基,萘基或取代的萘基; Ar 2是萘基,取代的萘基,喹啉基,由下式表示的基团:(其中R 4是氢原子或卤素原子; 并且XY是CH-NH,CH-O,CH-S或NO)或由下式表示的基团:(其中R 5是氢原子,羟基或C 1-10个烷氧基); R 1是氢原子,C 1-10烷基,C 3-8环烷基,C 3 -10个链烯基,苯基,1-氰基乙基,嘧啶-2-基或酰氨基; R 2和R 3相同或不同,并且各自为氢原子或C 1-10烷基; A-B是N-CH 2,CH-CH 2,C(OH)-CH 2或C-CH; T 1是单键,-N(R 6) - (其中R 6是氢原子或C 1 -10个烷基),-O - , - CH-CH-或-C( - O) - ; n是1〜10的整数,当T 1是单键时,-CH-CH-或-C(-O) - ,n是2〜10的整数,当T 或其药学上可接受的盐,其中R 1是-N(R 6) - 或-O-]。